To advance scientific discovery and improve patient outcomes, new programs being introduced to increase transparency in data collection and patient engagement are on the rise.
Despite education and intervention efforts, suicide rates are at a global all-time high. As surviving loved ones suffer, public health officials struggle to find solutions to a problem that is both pervasive and complex.
This common virus manifests in a host of systemic illnesses that are mostly curable with human intravenous immune globulin therapy.
A host of programs continue to be implemented in the United States and globally to address antibiotic-resistant illnesses.
Findings from Grifols’ Phase IIb Alzheimer Management by Albumin Replacement (AMBAR) clinical trial found long-term plasmapheresis with albumin replacement reduced disease progression in a prespecified subset of patients with AD of moderate severity.
Until more is discovered about the causes of autoimmune disorders, these chronic but sometimes fatal disorders will continue to increase in numbers of diseases and individuals affected.
Little is yet known about this vector-borne disease that has been diagnosed in only one human to date and appears confined to Gulf Coast states, but researchers are investigating to learn more.
